Trial
NCT01345669
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Boehringer Ingelheim
Collaborators
—
Condition
Head and Neck Neoplasms
Intervention
Placebo
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-07